ATE388167T1 - Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 - Google Patents

Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3

Info

Publication number
ATE388167T1
ATE388167T1 AT00962981T AT00962981T ATE388167T1 AT E388167 T1 ATE388167 T1 AT E388167T1 AT 00962981 T AT00962981 T AT 00962981T AT 00962981 T AT00962981 T AT 00962981T AT E388167 T1 ATE388167 T1 AT E388167T1
Authority
AT
Austria
Prior art keywords
ganglioside
derivatives
antibod
complementarity
transplantation
Prior art date
Application number
AT00962981T
Other languages
English (en)
Inventor
Nobuo Tokyo Hanai
Kenya Shitara
Kazuyasu Nakamura
Rinpei Niwa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE388167T1 publication Critical patent/ATE388167T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00962981T 1999-09-30 2000-09-29 Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 ATE388167T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27829199 1999-09-30
JP2000105088 2000-04-06

Publications (1)

Publication Number Publication Date
ATE388167T1 true ATE388167T1 (de) 2008-03-15

Family

ID=26552797

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00962981T ATE388167T1 (de) 1999-09-30 2000-09-29 Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3

Country Status (9)

Country Link
US (1) US7253263B1 (de)
EP (1) EP1238985B1 (de)
JP (1) JP4689124B2 (de)
AT (1) ATE388167T1 (de)
AU (1) AU784187B2 (de)
CA (1) CA2386197A1 (de)
DE (1) DE60038252T2 (de)
ES (1) ES2301491T3 (de)
WO (1) WO2001023432A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384487A4 (de) * 2001-03-29 2007-07-11 Kyowa Hakko Kogyo Kk Arzneimittel mit einem genetisch modifizierten antikörper gegen gangliosid gd3
CN100522998C (zh) 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
JPWO2005035577A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 ガングリオシドｇｄ３に特異的に結合する抗体組成物
US20070003557A1 (en) * 2005-04-21 2007-01-04 Andres Forero Method for treating cancer using premedication
EP3593812A3 (de) 2014-03-15 2020-05-27 Novartis AG Behandlung von krebs mithilfe eines chimären antigenrezeptors
WO2015195631A1 (en) * 2014-06-17 2015-12-23 Academia Sinica HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (de) 2015-04-23 2018-02-28 Novartis AG Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
EP3331913A1 (de) 2015-08-07 2018-06-13 Novartis AG Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP4043485A1 (de) 2017-01-26 2022-08-17 Novartis AG Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
EP3589647A1 (de) 2017-02-28 2020-01-08 Novartis AG Shp-inhibitor-zusammensetzungen und verwendungen zur chimären antigenrezeptortherapie
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
MX2020004229A (es) 2017-10-25 2020-07-22 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
EP3700933A1 (de) 2017-10-25 2020-09-02 Novartis AG Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
EP3784351A1 (de) 2018-04-27 2021-03-03 Novartis AG Car-t-zelltherapien mit erhöhter wirksamkeit
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (de) 2018-05-25 2021-04-14 Novartis AG Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car)
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924055B1 (de) 2019-02-15 2024-04-03 Novartis AG Substituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivate und verwendungen davon
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4330381A1 (de) 2021-04-27 2024-03-06 Novartis AG System zur herstellung von viralen vektoren
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US570078A (en) * 1896-10-27 Ardson
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5006470A (en) * 1987-04-16 1991-04-09 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens of melanoma
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4107154A1 (de) 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
ES2098304T3 (es) * 1990-11-30 1997-05-01 Kyowa Hakko Kogyo Kk Anticuerpos monoclonales frente a cadenas de hidratos de carbono glucolipidicas.
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
DE4208795A1 (de) * 1992-03-19 1993-09-23 Behringwerke Ag Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum
EP0867190B1 (de) 1995-05-10 2007-12-26 Kyowa Hakko Kogyo Co., Ltd. Cytotoxinkonjugate umfassend dipeptide
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
WO1999040118A1 (en) * 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Antibodies against human vegf receptor kdr

Also Published As

Publication number Publication date
EP1238985B1 (de) 2008-03-05
WO2001023432A1 (en) 2001-04-05
DE60038252T2 (de) 2009-03-19
CA2386197A1 (en) 2001-04-05
EP1238985A1 (de) 2002-09-11
AU7449100A (en) 2001-04-30
DE60038252D1 (de) 2008-04-17
JP4689124B2 (ja) 2011-05-25
US7253263B1 (en) 2007-08-07
EP1238985A4 (de) 2005-10-05
ES2301491T3 (es) 2008-07-01
AU784187B2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
ATE388167T1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
ATE364618T1 (de) Antikörper gegen das muc18-antigen
ATE394121T1 (de) Verwendung von antikörpern gegen das muc18- antigen
FR19C1028I2 (fr) Anticorps greffes avec cdr humains et fragments de ces anticorps
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR0208446A (pt) Agentes terapêuticos para doenças inflamatórias do intestino
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
DE69518406D1 (de) Monoklonale antikörper gegen den tie-rezeptor und deren verwendung
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
BR0213358A (pt) Uso de flibanserina
WO2003039462A3 (en) B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
CA2376497A1 (fr) Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
EA200300507A1 (ru) Радиофармацевтические агенты для диагностики болезни альцгеймера
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
ATE346067T1 (de) Carbolinderivate
ITNA20000036A0 (it) Nuovi approcci terapeutici per il trattamento della forfora.
ITBO20030261A1 (it) Unita'di irraggiamento luminoso per diagnosi e cura di problemi cutanei.
ITFI20020176A1 (it) Immunoglobulina specifica per callicreina tessutale umana, formulazione immunologica comprendente detta immunoglobulina e relativo kit diagnostico per la diagnosi dell'ischemia cerebrale.
ITRM20020576A1 (it) Mezzi diagnostici e terapeutici per patologie correlate all'emicrania.
ITRM980795A0 (it) Anticorpi monoclonali per la diagnosi di patologie da fitoplasmi del melo, metodo diagnostico e kit relativo
ITMO20030105A0 (it) Dispositivo d'infusione per uso medicale.
ITMI20001776A0 (it) Apparecchiatura e relativo metodo non invasivo per la diagnosi precoce della malattia di alzheimer.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties